The myelofibrosis market is projected to increase from $545.2m last year to $1.02bn by 2025, according to a report by GlobalData.
Titled 'OpportunityAnalyzer: Myelofibrosis – Opportunity Analysis and Forecasts to 2025', the report provides forecast for the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK and Japan.
Growth in the myelofibrosis market is projected to be mainly driven by the launch of pipeline agents such as Gilead’s momelotinib, Promedior’s PRM-151, and Johnson & Johnson/Geron’s imetelstat. Increase in the incidence of myelofibrosis, and use of drugs targeting splenomegaly and constitutional symptoms are some of the other reasons responsible for the growth.
Incyte/Novartis’ Jakafi is currently the only drug approved for the treatment of the splenomegaly and constitutional symptoms associated with myelofibrosis. No other approved drug is available for patients who have become unresponsive to Jakafi. Momelotinib and imetelstat, scheduled to be launched next year and 2021 respectively, are expected to address this gap.
Imetelstat, a first-in-class telomerase inhibitor, however, may face difficulties in market penetration due to late market entry and a high level of toxicity demonstrated in earlier clinical trials, opines James Beggs, GlobalData’s Analyst covering oncology and haematology. Sales of the drug in 2025 are estimated to be $21.2m, which is 2% of the myelofibrosis market in the 7MM.
The other drug under development, PRM-151, is expected to be more successful due to its positive anti-fibrotic effects and capability to reduce dependency on treatments for anaemia, splenomegaly, and constitutional symptoms. The drug is expected to capture significant market share by fulfilling these unmet needs.
Despite the emergence of the new drugs, Jakafi is expected to retain its leading position in the market, holding more than 50% of the market share in 2025. Jakafi has the advantages of being first-to-market and having proven long-term efficacy and safety profile.